GlassScriptPhysician profile
John A Prevedel
NPI 1831185776
$2,876.16
in general payments reported to CMS, 2019-2025
28 companies · $95.84 in 2025
The $95.84 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $206 · 2021: $94.16 · 2022: $447 · 2023: $670 · 2024: $605 · 2025: $95.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,370.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $284.29 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $245.17 | 2021-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $238.04 | 2019-2023 | Xarelto |
| Pfizer INC. | $215.59 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.18 | 2019-2024 | Jardiance |
| Amgen INC. | $165.08 | 2019-2024 | Repatha |
| Medtronic, INC. | $157.21 | 2021-2023 | Telescope |
| Sanofi-Aventis U.S. LLC | $155.65 | 2019-2024 | |
| Shockwave Medical, INC | $154.79 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| E.R. Squibb & Sons, L.L.C. | $153.32 | 2019-2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $141.15 | 2020-2024 | Wainua, Lokelma, Farxiga |
| Heartflow, INC. | $106.34 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $102.46 | 2023-2024 | Onpattro, Amvuttra |
| Kiniksa Pharmaceuticals, LTD. | $75.23 | 2021-2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $70.73 | 2022-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $53.53 | 2019-2023 | |
| Abiomed | $53.29 | 2019-2024 | Impella |
| Novo Nordisk INC | $44.41 | 2023-2024 | Ozempic, Wegovy |
| Cvrx, INC. | $39.62 | 2023-2024 | Barostim Neo System |
| Amarin Pharma, INC. | $37.25 | 2019 | |
| Edwards Lifesciences Corporation | $31.08 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Esperion Therapeutics, INC. | $26.66 | 2021 | |
| Abbott Laboratories | $24.52 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.05 | 2019-2020 | |
| Boston Scientific Corporation | $22.63 | 2020 | |
| Gilead Sciences, INC. | $19.39 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.57 | 2019 | |
| Medtronic Vascular, INC. | $14.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Prevedel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.